Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ:CTNM) — Stock Price
Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ:CTNM) is currently trading at $14.49 USD, down 3.66% today. Over the past 52 weeks, shares have ranged between $6.75 and $16.39. This page tracks Contineum Therapeutics, Inc. Class A Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see CTNM market cap.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Contineum Therapeutics, Inc. Class A Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Contineum Therapeutics, Inc. Class A Common Stock Income Statement — Revenue, Profit & Earnings by Year
Contineum Therapeutics, Inc. Class A Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $50.00 Million | $0.00 | $0.00 |
| Cost of Revenue | $323.00K | $258.00K | $195.00K | $329.00K | — |
| Gross Profit | $-323.00K | $-258.00K | $50.00 Million | $-329.00K | — |
| Research & Development | $51.52 Million | $38.16 Million | $27.60 Million | $16.89 Million | $22.36 Million |
| SG&A | $16.54 Million | $12.47 Million | $6.32 Million | $5.83 Million | $6.29 Million |
| Total Operating Expenses | $68.06 Million | $50.64 Million | $66.08 Million | $22.39 Million | $28.65 Million |
| Operating Income | $-68.06 Million | $-50.89 Million | $-16.08 Million | $-22.72 Million | $-28.65 Million |
| EBITDA | $-67.74 Million | $-42.00 Million | $23.57 Million | $-23.54 Million | $-28.34 Million |
| EBIT | $-68.06 Million | $-42.26 Million | $23.38 Million | $-23.86 Million | $-28.66 Million |
| Interest Expense | — | $0.00 | $208.00K | $388.00K | $332.00K |
| Income Before Tax | $-59.98 Million | $-42.26 Million | $23.17 Million | $-24.25 Million | $-29.00 Million |
| Income Tax Expense | — | — | $450.00K | — | $241.00K |
| Net Income | $-59.98 Million | $-42.26 Million | $22.72 Million | $-24.25 Million | $-29.00 Million |
Contineum Therapeutics, Inc. Class A Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Contineum Therapeutics, Inc. Class A Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $276.64 Million | $212.85 Million | $130.39 Million | $50.64 Million | $70.52 Million |
| Total Current Assets | $267.92 Million | $206.39 Million | $127.71 Million | $48.39 Million | $69.78 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $187.29 Million | $182.82 Million | $109.66 Million | $41.67 Million | $64.37 Million |
| Net Receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $15.65 Million | $14.78 Million | $198.32 Million | $11.37 Million | $8.93 Million |
| Total Current Liabilities | $9.74 Million | $9.97 Million | $5.48 Million | $7.55 Million | $3.67 Million |
| Long-term Debt | — | — | — | — | $3.66 Million |
| Net Debt | $-67.35 Million | $-15.68 Million | $177.67 Million | $280.00K | $279.00K |
| Total Stockholder Equity | $260.99 Million | $198.07 Million | $-67.94 Million | $39.27 Million | $61.59 Million |
| Retained Earnings | $-177.38 Million | $-117.40 Million | $-75.14 Million | $-97.86 Million | $-73.61 Million |
Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Contineum Therapeutics, Inc. Class A Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-55.31 Million | $-32.84 Million | $19.35 Million | $-20.12 Million | $-26.27 Million |
| Capital Expenditures | $231.00K | $514.00K | $414.00K | $118.00K | $168.00K |
| Free Cash Flow | $-55.54 Million | $-33.36 Million | $18.93 Million | $-20.24 Million | $-26.43 Million |
| Investing Cash Flow | $-3.71 Million | $-69.74 Million | $-65.57 Million | $22.30 Million | $-64.97 Million |
| Financing Cash Flow | $112.69 Million | $109.00 Million | $56.18 Million | $-1.24 Million | $79.84 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $10.04 Million | $6.80 Million | $2.22 Million | $1.93 Million | $1.75 Million |
| Depreciation | $323.00K | $258.00K | $195.00K | $329.00K | $325.00K |
| Change in Cash | $53.66 Million | $6.42 Million | $9.96 Million | $939.00K | $-11.39 Million |
Contineum Therapeutics, Inc. Class A Common Stock Earnings History — EPS Actual vs. Analyst Estimates
Track Contineum Therapeutics, Inc. Class A Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.39 | -0.85 | +54.12% |
| Mar 05, 2026 | -0.49 | -0.65 | +24.62% |
| Oct 30, 2025 | -0.45 | -0.60 | +25.00% |
| Aug 06, 2025 | -0.62 | -0.28 | -121.43% |
| May 15, 2025 | -0.62 | -0.42 | -47.62% |
| Mar 06, 2025 | -0.56 | -0.43 | -30.23% |
| Nov 06, 2024 | -0.40 | -0.41 | +2.44% |
| Aug 13, 2024 | -0.39 | -0.35 | -11.43% |